Related Experiment Video

Updated: Sep 27, 2026

Analysis of Cell Cycle Position in Mammalian Cells
12:19

Analysis of Cell Cycle Position in Mammalian Cells

Published on: January 21, 2012

Mitogen-activated protein kinase inhibitor, PD98059, inhibits rat retinal pigment epithelial cell replication by cell

Katsuhiro Yamaguchi1, Hiroshi Tomita, Eriko Sugano

  • 1Department of Ophthalmology, Tohoku University School of Medicine, Sendai, Japan.

Japanese Journal of Ophthalmology
|January 25, 2003
PubMed
Abstract

Insights

Mitogen-activated protein kinase (MAPK) inhibition with PD98059 arrested cell cycle progression in rat retinal pigment epithelial (RPE) cells at the G0/G1 phase, offering a potential therapeutic strategy for proliferative vitreoretinopathy.

Area of Science:

  • Cell Biology
  • Pharmacology
  • Ophthalmology

Background:

  • Retinal pigment epithelial (RPE) cells play a crucial role in retinal health.
  • Uncontrolled RPE cell proliferation is implicated in conditions like proliferative vitreoretinopathy.
  • Understanding mechanisms to control RPE cell proliferation is vital for therapeutic development.

Purpose of the Study:

  • To investigate the effect of PD98059, a MAPK inhibitor, on the proliferation of cultured rat RPE cells.
  • To determine if PD98059 affects RPE cell viability and cell cycle progression.

Main Methods:

  • Cultured rat RPE cells were treated with varying concentrations of PD98059.
  • Cell proliferation was quantified using cell counts.
  • Cell viability was assessed using a non-radioactive proliferation assay.
  • Nuclear morphology and cell cycle phase were analyzed via Hoechst/propidium iodide staining and Ki67 immunostaining.

Main Results:

  • PD98059 inhibited RPE cell proliferation in a dose-dependent manner.
  • No significant cell death was observed following PD98059 treatment.
  • Ki67 staining indicated cell cycle arrest at the G0/G1 phase 24 hours post-treatment.

Conclusions:

  • MAPK inhibition by PD98059 effectively arrests the cell cycle of rat RPE cells at the G0/G1 phase.
  • Pharmacological induction of cell cycle arrest presents a novel therapeutic approach for inhibiting RPE cell proliferation.
  • This strategy holds promise for treating conditions such as proliferative vitreoretinopathy.

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues08:06

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues

Published on: July 8, 2020

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...